Stock of the Day

Lexicon Pharmaceuticals (LXRX)

$0.70

+$0.01 (+1.7%)

Market Cap: $253.41M

About Lexicon Pharmaceuticals

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract.

Lexicon Pharmaceuticals, Inc. has strategic collaboration and license agreements with Bristol-Myers Squibb Company and Genentech, Inc. The company was incorporated in 1995 and is headquartered in The Woodlands, Texas.

Recent News

• Lexicon Pharmaceuticals to Present at the 3rd Annual H.C. Wainwright BioConnect Investor Conference (gurufocus.com)
• Lexicon Pharmaceuticals to Present at the 3rd Annual H.C. ... (gurufocus.com)
• Lexicon Pharmaceuticals to Present at the 3rd Annual H.C. Wainwright BioConnect Investor Conference (globenewswire.com)
• Lexicon Pharmaceuticals to Report First Quarter 2025 Financial Results on May 13, 2025 (gurufocus.com)
• Lexicon Pharmaceuticals to Report First Quarter 2025 Financial Results on May 13, 2025 (globenewswire.com)